Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. The company's lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b clinical trial. It also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. It has a research collaboration with Amsterdam University Medical Center to develop a blood based test that measures naturally occurring antibodies against toxic amyloid ß oligomers. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden.…
Alzinovas vaccinkandidat går vidare till fas II samtidigt som bolaget genomför en företrädesemission
Alzinova (STO: ALZ) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 7 employees.
The shares were at 0.3095 SEK on 20 November 2026, down 76.0% over 52 weeks. Its 52-week range is 0.2845 SEK to 2.070 SEK: the price is 85.0% below the high and 8.8% above the low.
Its market capitalisation is 97.82M SEK.
Alzinova reports return on equity of -21.5% and an operating margin of -121.4%.
Its debt exceeds its cash by 56.00K SEK, a debt-to-equity ratio of 0.01. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 2 analysts cover the stock; their mean price target of 1.200 SEK is 287.7% above the current price.
No upcoming events tracked.